Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment Expects topline results by the end of July LAWRENCEVILLE, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage company in advanced development of its non-viral DNA-mediated immunotherapy, announces database lock for its Phase 2 OVATION 2 Study evaluating the safety and efficacy of IMNN-001 in patients with advanced ovarian cancer. Median Overall Survival (OS) and Progression Free Survival (PF ...

Novel IL-12 Immunotherapy Administered with Standard of Care as First-Line Treatment Expects topline results by the end of July LAWRENCEVILLE, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in advanced development of its non-viral DNA-mediated immunotherapy, announces database lock for its Phase 2 OVATION 2 Study evaluating the safety and efficacy of IMNN-001 in patients with advanced ovarian cancer. Median Overall Survival (OS) and Progression Free Survival (P ...

DNA vaccine proof-of-concept study expected to demonstrate an “mRNA better” platform LAWRENCEVILLE, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapy and evaluating an adaptation of the platform’s potential as a next-generation vaccine, announces that the first participants have been treated in the IMNN-101 Phase 1 clinical trial. This proof-of-concept study of IMUNON’s proprietary PlaCCine® platform is be ...

LAWRENCEVILLE, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that an abstract describing a Phase 2 study with IMNN-001 plus bevacizumab (Avastin®) and neoadjuvant chemotherapy in advanced epithelial ovarian cancer patients has been accepted for presentation at the American Society of Clinical Oncology (ASCO) annual meeting, to be held in Chicago fr ...

财务数据和关键指标变化 - 截至2024年3月31日,公司现金及投资为9.8亿美元 [50] - 2024年第一季度现金使用5.9亿美元,较上年同期的4亿美元增加,主要是由于与OPTIMA III期临床试验相关的CRO成本最终支付 [50] - 2024年第一季度净亏损4.9亿美元,较上年同期的5.6亿美元减少 [53][54] - 2024年第一季度研发费用3.3亿美元,较上年同期增加0.7亿美元,主要用于IMNN-001和PlaCCine DNA疫苗技术平台的开发 [55] - 2024年第一季度一般及行政费用1.7亿美元,较上年同期减少1.4亿美元,主要由于股份支付费用、员工相关成本、咨询和法律费用以及董事和高管责任保险费用降低 [58] 各条业务线数据和关键指标变化 - OVATION 2临床试验第三季度2022年完成入组113例患者,2023年报告了中期数据,显示PFS和OS有改善趋势 [24][30] - 公司正在进行另一项IMNN-001在晚期卵巢癌患者中的临床试验,由Breakthrough Cancer Foundation提供资金,预计入组50例患者 [33][34][35][36] - 公司已启动IMNN-101 COVID-19疫苗的首次人体试验,目标是评估安全性、耐受性、中和抗体反应和持久性 [38][39][40][41][42][43] 各个市场数据和关键指标变化 - 卵巢癌是一种严重的疾病,在美国每年约有2万例新诊断病例,1.3万例死亡病例 [14] - 全球约有25万名妇女患有卵巢癌 [14] 公司战略和发展方向及行业竞争 - 公司正专注于推进TheraPlas和PlaCCine两大技术平台的临床开发 [16][19][22][23] - 公司相信IMNN-001可能成为首个有效治疗晚期卵巢癌的免疫治疗药物 [14][37] - IMNN-101 COVID-19疫苗有望展现出优于mRNA疫苗的免疫原性、安全性和稳定性 [46][47] - 公司计划将IMNN-101疫苗项目进行商业合作,以推动该技术平台在其他传染病领域的应用 [47] 管理层对经营环境和未来前景的评论 - 新任CEO Stacy Lindborg表示,公司拥有出色的科学和运营团队,TheraPlas和PlaCCine技术平台前景广阔 [14][15][16][18][19] - 公司对IMNN-001在卵巢癌治疗中的潜力持乐观态度,中期数据显示PFS和OS有改善趋势 [26][27][28][29][30][31][32] - 公司对IMNN-101 COVID-19疫苗的免疫原性、安全性和稳定性特点持乐观态度,认为其有望在传染病领域展现优势 [46][47] 问答环节重要的提问和回答 问题1 **Emily Bodnar 提问** 询问IMNN-101 COVID-19疫苗临床试验的剂量设计和公司对疫苗免疫原性及持久性的内部目标 [67][68] **Khursheed Anwer 回答** 公司在动物实验中已经确定了有效剂量范围,这些剂量将在人体试验中进行评估。公司对疫苗的免疫原性和持久性持乐观态度 [70] 问题2 **Kemp Dolliver 提问** 询问公司对OVATION 2临床试验结果的预期,以及未来可能的III期临床试验设计 [82][83][84] **Stacy Lindborg 回答** 公司将根据OVATION 2最终结果设计III期试验,需要考虑PARP抑制剂等新兴治疗的影响。公司希望能够包括广泛的患者人群,而不是过度缩小研究对象 [85][86][87][88][89] 问题3 **James Molloy 提问** 询问公司对IMNN-001联合checkpoint抑制剂的组合疗法的计划,以及IMNN-101 COVID-19疫苗的预期数据时间表 [100][101][102][103][104][105][106][107] **Michael Tardugno 和 Sebastien Hazard 回答** 公司目前正专注于保守资金使用,暂时没有IMNN-001联合checkpoint抑制剂的具体计划。预计在今年年底前公布IMNN-101 COVID-19疫苗的初步免疫原性和安全性数据 [103][104][107]

Proof-of-concept study for Imunon's first vaccine utilizing its proprietary PlaCCine platform is now open for enrollment Topline results expected this year LAWRENCEVILLE, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced that DM Clinical Research in Philadelphia is the first site activated and ready for patient recruitment for its Phase 1 study w ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number: 001-15911 Imunon, Inc. (Exact name of Registrant as specified in its charter) Delaware 52-1256615 (State ...

Exhibit 99.1 IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (May 13, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the three months ended March 31, 2024. The Company also provided an update on its clinical development programs with IMNN-001, ...

Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and business strategy LAWRENCEVILLE, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024. Dr ...

LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Monday, May 13, 2024 to discuss financial results for the first quarter ended March 31, 2024 and provide an update on its clinical development programs with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinica ...